Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4104968 | 0.92 | TSHR (0.43) | TSHREPHX2MAPTHSD17B10MEN1 | |
| SCHEMBL4093922 | 0.87 | MAPT (0.42) | TSHREPHX2MAPTHSD17B10MEN1 | |
| SCHEMBL18239183 | 0.86 | TSHR (0.45) | TSHREPHX2MAPTHSD17B10MEN1 | |
| SCHEMBL4093599 | 0.85 | MEN1 (0.46) | EPHX2MAPTMEN1THRBHTT | |
| SCHEMBL4103946 | 0.85 | EPHX2 (0.36) | TSHREPHX2MAPTHSD17B10RECQL | |
| SCHEMBL18239181 | 0.83 | TSHR (0.42) | TSHREPHX2MAPTHSD17B10MEN1 | |
| SCHEMBL16562990 | 0.83 | TSHR (0.52) | TSHREPHX2MAPTHSD17B10MEN1 | |
| SCHEMBL4093404 | 0.82 | MEN1 (0.37) | TSHREPHX2MEN1THRBKMT2A | |
| SCHEMBL4095312 | 0.82 | MEN1 (0.37) | TSHREPHX2MEN1THRBKMT2A | |
| SCHEMBL4111859 | 0.82 | ALDH1A1 (0.37) | TSHREPHX2MEN1THRBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160333052-A1 | NOVEL CROSS-LINKED PEPTIDES CONTAINING NON-PEPTIDE CROSS-LINKED STRUCTURE, METHOD FOR SYNTHESIZING CROSS-LINKED PEPTIDES, AND NOVEL ORGANIC COMPOUND USED IN METHOD | JITSUBO CO., LTD. (JP) | 2016-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160333052-A1 | NOVEL CROSS-LINKED PEPTIDES CONTAINING NON-PEPTIDE CROSS-LINKED STRUCTURE, METHOD FOR SYNTHESIZING CROSS-LINKED PEPTIDES, AND NOVEL ORGANIC COMPOUND USED IN METHOD | NRDC, VIP, NRP1 | TSHR 1379/4885EPHX2 865/4885MAPT 3893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.